Search

Your search keyword '"Belda-Iniesta, C."' showing total 252 results

Search Constraints

Start Over You searched for: Author "Belda-Iniesta, C." Remove constraint Author: "Belda-Iniesta, C."
252 results on '"Belda-Iniesta, C."'

Search Results

1. Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

19. Potential Therapeutic Effects of the Neural Stem Cell-Targeting Antibody Nilo1 in Patient-Derived Glioblastoma Stem Cells

23. OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study

24. Polyethylene glycol improves current methods for circulating extracellular vesicle-derived DNA isolation

28. Extracellular vesicles compartment in liquid biopsies: Clinical application

30. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O(6)-Methylguanine-DNA Methyltransferase Biomarker Analyses

34. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study

35. DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients

36. Cancer stem cells from human glioblastoma resemble but do not mimic original tumors after in vitro passaging in serum-free media

38. Engineering Iron Oxide Nanoparticles for Clinical Settings

39. Engineering Iron Oxide Nanoparticles for Clinical Settings

41. ET-12 * PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

42. Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC)

43. Identification of drug-sensitive prediction genes by an epigenetic reactivation screen of cisplatin-resistant NSCLC cell lines

45. Do β-tubulin pseudogenes really matter?

47. PCN88 Cost-Effectiveness Analysis Per Life-Year Gained Based on Predictors of Response for First Line Metastasic Colorectal Cancer Therapy in Spain

Catalog

Books, media, physical & digital resources